ME02633B - Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro [cikloheksan-1,2'-inden-1'2'-imidazol]-4"amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti - Google Patents
Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro [cikloheksan-1,2'-inden-1'2'-imidazol]-4"amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolestiInfo
- Publication number
- ME02633B ME02633B MEP-2017-61A MEP201761A ME02633B ME 02633 B ME02633 B ME 02633B ME P201761 A MEP201761 A ME P201761A ME 02633 B ME02633 B ME 02633B
- Authority
- ME
- Montenegro
- Prior art keywords
- disease
- alzheimer
- dementia
- related pathology
- pharmaceutical composition
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 claims 12
- 230000007170 pathology Effects 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010036631 Presenile dementia Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662592P | 2012-06-21 | 2012-06-21 | |
| EP13733415.7A EP2864316B1 (en) | 2012-06-21 | 2013-06-20 | Camsylate salt of (1r,1'R,4R)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'H-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine and crystalline forms thereof for the treatment of A[beta]-related pathologies such as e.g. Alzheimer's disease |
| PCT/GB2013/051606 WO2013190302A1 (en) | 2012-06-21 | 2013-06-20 | Camsylate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02633B true ME02633B (me) | 2017-06-20 |
Family
ID=48746084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-61A ME02633B (me) | 2012-06-21 | 2017-03-08 | Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro [cikloheksan-1,2'-inden-1'2'-imidazol]-4"amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti |
Country Status (42)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
| US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| AR102202A1 (es) | 2014-10-07 | 2017-02-08 | Astrazeneca Ab | Compuestos de oxazol y su uso como inhibidores de bace de oxazol |
| JP6546410B2 (ja) * | 2015-02-23 | 2019-07-17 | ローム株式会社 | 電力供給装置、ａｃアダプタ、ａｃチャージャ、電子機器および電力供給システム |
| CN109195630A (zh) * | 2016-03-15 | 2019-01-11 | 阿斯利康(瑞典)有限公司 | 用于治疗与淀粉样蛋白β累积相关的病症的BACE抑制剂和抗体或抗原结合片段的组合 |
| TW201740944A (zh) | 2016-03-15 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
| CA3131753A1 (en) | 2019-03-14 | 2020-09-17 | Astrazeneca Ab | Lanabecestat for weight loss |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100452491B1 (ko) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
| JP4273406B2 (ja) | 2001-06-01 | 2009-06-03 | 小野薬品工業株式会社 | アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤 |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| ATE445399T1 (de) | 2004-03-22 | 2009-10-15 | Lilly Co Eli | Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten |
| CA2609582A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| WO2007058601A1 (en) | 2005-11-21 | 2007-05-24 | Astrazeneca Ab | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia |
| TW200734311A (en) * | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| JP2009521488A (ja) | 2005-12-21 | 2009-06-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体 |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| AU2007258435A1 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2008076044A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
| WO2008092877A2 (en) | 2007-02-01 | 2008-08-07 | Glaxo Group Limited | 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders |
| EP2155737A1 (en) | 2007-05-07 | 2010-02-24 | Schering Corporation | Gamma secretase modulators |
| WO2009100169A1 (en) | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| FR2929943B1 (fr) * | 2008-04-15 | 2010-09-24 | Inst Rech Developpement Ird | Sels de quinoleines 2-substituees |
| KR20110048491A (ko) | 2008-07-28 | 2011-05-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스피로아미노디하이드로티아진 유도체들 |
| US8450308B2 (en) | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| CA2736130C (en) | 2008-09-11 | 2014-01-14 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| BRPI1009333B8 (pt) | 2009-03-13 | 2021-05-25 | Boehringer Ingelheim Int | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica |
| UY32750A (es) | 2009-07-02 | 2011-01-31 | Astrazeneca Ab | Imidazoles sustituidos y uso de los mismos |
| TW201105650A (en) | 2009-07-02 | 2011-02-16 | Astrazeneca Ab | New compounds |
| JP5828848B2 (ja) | 2010-02-24 | 2015-12-09 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | ベータセクレターゼインヒビター |
| US20120065195A1 (en) | 2010-03-31 | 2012-03-15 | Clark Christopher T | Compounds for treating neurodegenerative diseases |
| WO2011130741A1 (en) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| EP2601197B1 (en) | 2010-08-05 | 2014-06-25 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| WO2012040641A2 (en) | 2010-09-24 | 2012-03-29 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| AR083953A1 (es) | 2010-11-22 | 2013-04-10 | Array Biopharma Inc | Compuestos para tratar enfermedades neurodegenerativas |
| US8415483B2 (en) * | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
-
2013
- 2013-06-13 US US13/916,754 patent/US10548882B2/en active Active
- 2013-06-19 AR ARP130102162 patent/AR091495A1/es unknown
- 2013-06-20 JP JP2015517850A patent/JP2015520221A/ja active Pending
- 2013-06-20 NZ NZ727045A patent/NZ727045A/en not_active IP Right Cessation
- 2013-06-20 WO PCT/GB2013/051606 patent/WO2013190302A1/en not_active Ceased
- 2013-06-20 MX MX2014014709A patent/MX354214B/es active IP Right Grant
- 2013-06-20 EP EP16162104.0A patent/EP3064494A1/en not_active Withdrawn
- 2013-06-20 PT PT137334157T patent/PT2864316T/pt unknown
- 2013-06-20 DK DK13733415.7T patent/DK2864316T3/en active
- 2013-06-20 BR BR112014031531-0A patent/BR112014031531B1/pt active IP Right Grant
- 2013-06-20 LT LTEP13733415.7T patent/LT2864316T/lt unknown
- 2013-06-20 SI SI201330561A patent/SI2864316T1/sl unknown
- 2013-06-20 IN IN10088DEN2014 patent/IN2014DN10088A/en unknown
- 2013-06-20 RS RS20170236A patent/RS55815B1/sr unknown
- 2013-06-20 AP AP2014008137A patent/AP2014008137A0/xx unknown
- 2013-06-20 MA MA39259A patent/MA39259B1/fr unknown
- 2013-06-20 CN CN201610570484.2A patent/CN106279102A/zh active Pending
- 2013-06-20 AP AP2017009693A patent/AP2017009693A0/en unknown
- 2013-06-20 CN CN201380033030.6A patent/CN104411697B/zh active Active
- 2013-06-20 RU RU2014148305A patent/RU2638175C2/ru active
- 2013-06-20 AU AU2013279109A patent/AU2013279109B2/en active Active
- 2013-06-20 ES ES13733415.7T patent/ES2618939T3/es active Active
- 2013-06-20 SG SG11201407934UA patent/SG11201407934UA/en unknown
- 2013-06-20 HU HUE13733415A patent/HUE033376T2/en unknown
- 2013-06-20 PE PE2014002451A patent/PE20150670A1/es active IP Right Grant
- 2013-06-20 SM SM20170142T patent/SMT201700142T1/it unknown
- 2013-06-20 HR HRP20170359TT patent/HRP20170359T1/hr unknown
- 2013-06-20 BR BR122016014302-3A patent/BR122016014302B1/pt active IP Right Grant
- 2013-06-20 NZ NZ702742A patent/NZ702742A/en not_active IP Right Cessation
- 2013-06-20 EP EP13733415.7A patent/EP2864316B1/en active Active
- 2013-06-20 KR KR1020147035069A patent/KR102123708B1/ko active Active
- 2013-06-20 PL PL13733415T patent/PL2864316T3/pl unknown
- 2013-06-20 CA CA2875589A patent/CA2875589C/en active Active
- 2013-06-20 UA UAA201412619 patent/UA114196C2/uk unknown
- 2013-06-21 TW TW102122259A patent/TWI588140B/zh not_active IP Right Cessation
- 2013-06-21 TW TW106115007A patent/TWI639591B/zh not_active IP Right Cessation
-
2014
- 2014-11-25 DO DO2014000268A patent/DOP2014000268A/es unknown
- 2014-11-25 TN TN2014000491A patent/TN2014000491A1/fr unknown
- 2014-12-08 IL IL236131A patent/IL236131A0/en active IP Right Grant
- 2014-12-10 MA MA37666A patent/MA37666B1/fr unknown
- 2014-12-11 CR CR20140571A patent/CR20140571A/es unknown
- 2014-12-11 CL CL2014003374A patent/CL2014003374A1/es unknown
- 2014-12-16 PH PH12014502803A patent/PH12014502803B1/en unknown
- 2014-12-18 CO CO14278352A patent/CO7151486A2/es unknown
- 2014-12-18 NI NI201400146A patent/NI201400146A/es unknown
- 2014-12-18 EC ECIEPI201432215A patent/ECSP14032215A/es unknown
-
2015
- 2015-01-20 ZA ZA2015/00408A patent/ZA201500408B/en unknown
-
2016
- 2016-03-14 PH PH12016500498A patent/PH12016500498A1/en unknown
- 2016-04-29 CR CR20160202A patent/CR20160202A/es unknown
- 2016-06-28 AR ARP160101953A patent/AR105176A2/es unknown
-
2017
- 2017-03-08 ME MEP-2017-61A patent/ME02633B/me unknown
- 2017-03-13 CY CY20171100314T patent/CY1119505T1/el unknown
- 2017-11-03 AU AU2017254965A patent/AU2017254965B2/en not_active Ceased
-
2018
- 2018-02-09 JP JP2018021595A patent/JP6509393B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02633B (me) | Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro [cikloheksan-1,2'-inden-1'2'-imidazol]-4"amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti | |
| ME02728B (me) | Jedinjenja i njihova upotreba kao bace inhibitori | |
| JP2015520221A5 (en:Method) | ||
| BR112014029016A2 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| EA201190020A1 (ru) | Производные изоиндола в качестве ингибиторов васе и их применение | |
| CL2008002271A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson. | |
| HRP20160185T1 (hr) | Spojevi iminotiadiazin dioksida kao inhibitori bace, smjese i njihova uporaba | |
| BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
| HRP20161742T1 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
| BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| ME02390B (me) | Inhibitori beta sekretaze | |
| MX2013009709A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7. | |
| AR075152A1 (es) | Preparacion y aplicaciones terapeuticas de (2s, 3r)-n-2-((3-piridinil)metil)-1-azabiciclo(2.2.2.)oct-3-il)-3,5-difluorobenzamida | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| MX344696B (es) | Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson. | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| HK1206351A1 (en) | Cycloalkyl ether compounds and their use as bace inhibitors | |
| JP2015500300A5 (en:Method) | ||
| HK1206348A1 (en) | Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| PH12013501509A1 (en) | Treatment of cognitive dysfunction in schizophrenia | |
| WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
| WO2013043744A3 (en) | Tricyclic compounds useful as neurogenic and neuroprotective agents | |
| WO2016119031A8 (pt) | Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase | |
| TN2013000345A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators |